Ligand Pharmaceuticals (LGND) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 58% year-over-year to $41.5M, driven by new product approvals, milestone payments, and higher royalties, with the portfolio expanding to 12 major commercial-stage assets, including Capvaxive, Ohtuvayre, and Qarziba following the $100M Apeiron acquisition.

• Maintains a high-margin, high-growth strategy with a lean cost structure and diversified investment approach, supported by significant deployable capital and expanded credit facility.

• GAAP net loss from continuing operations was $51.9M, mainly due to non-cash impairments and investment write-downs, compared to net income of $2.3M in Q2 2023.

• Key leadership changes include the departure of President and COO Matt Korenberg, who will remain as a consultant through year-end.

Financial highlights

• Q2 2024 total revenue reached $41.5M, up 58% year-over-year, with royalty revenue at $23.2M, up 11%, and Captisol sales at $7.5M, up 44%.

• Core adjusted EPS was $1.40, up 121% from Q2 2023, and adjusted net income was $25.8M.

• GAAP net loss of $51.9M resulted from $26.5M impairment on Soticlestat and $32M on Primrose Bio.

• Cash and short-term investments totaled $226.9M as of June 30, 2024, with access to a $125M credit facility.

• Operating costs rose 114% to $60.6M, mainly due to impairments.

Outlook and guidance

• 2024 guidance reaffirmed: total revenue of $140M–$157M, royalty revenue of $100M–$105M, and core adjusted EPS of $5.00–$5.50.

• Long-term outlook targets royalty revenue CAGR above 20% and adjusted EPS above $10 per share by 2028.

• Investment activity expected to be around $200M per year, with typical deal sizes of $30M–$40M per asset.